Rapport Therapeutics (RAPP) officer flags $553K stock sale plan

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) is the issuer of common stock that an officer, Krishnaswamy Yeleswaram, has notified for potential resale under Rule 144. The notice covers 11,472 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing lists an approximate market value of $553,409.28 for these shares and an approximate number of shares of the same class outstanding of 47,978,286. During the past three months, a separate Rule 10b5-1 sale of 404 shares for $20,159.60 is reported. The securities to be sold were acquired upon the vesting of founders shares between June 9, 2024 and August 20, 2024.

Key Figures

Shares to be sold: 11,472 shares Aggregate market value of shares to be sold: $553,409.28 Shares outstanding of same class: 47,978,286 shares +3 more

6 metrics

Shares to be sold 11,472 shares Common stock covered by the Rule 144 notice

Aggregate market value of shares to be sold $553,409.28 Value associated with 11,472 shares in the Rule 144 notice

Shares outstanding of same class 47,978,286 shares Approximate number of Rapport Therapeutics common shares outstanding

Shares sold in past 3 months 404 shares 10b5-1 sale reported for the past three months

Proceeds from past 3 months sale $20,159.60 Total consideration for the 404-share 10b5-1 sale

Date of Notice 08/24/2026 Date on which the Rule 144 notice was signed

Key Terms

Rule 144, founders shares, 10b5-1

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

founders shares financial

"The securities to be sold were acquired upon the vesting of founders shares"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

10b5-1 regulatory

"10b5-1 Sales for KRISHNASWAMY 99 High Street"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

FAQ

What does the Form 144 filing disclose for Rapport Therapeutics (RAPP)?

It discloses that an officer, Krishnaswamy Yeleswaram, has filed a notice under Rule 144 to potentially sell 11,472 shares of Rapport Therapeutics common stock, with an indicated market value of $553,409.28, through Morgan Stanley Smith Barney LLC Executive Financial Services.

How many Rapport Therapeutics (RAPP) shares are covered by this planned Rule 144 sale?

The notice covers 11,472 shares of common stock of Rapport Therapeutics, Inc. This is the amount listed in the securities information and securities-to-be-sold sections for the planned Rule 144 transaction.

What is the reported market value of the RAPP shares in this Form 144?

The Form 144 lists an aggregate market value of $553,409.28 for the 11,472 shares of Rapport Therapeutics common stock referenced in the notice, based on the information provided in the securities information section.

How many Rapport Therapeutics (RAPP) shares of this class are outstanding, according to the filing?

The filing reports an approximate number of 47,978,286 shares of the same class of Rapport Therapeutics common stock outstanding. This figure is presented as context for the size of the potential Rule 144 sale.

What prior sales by the officer are reported in the past three months for RAPP?

The filing reports a 10b5-1 sale for Krishnaswamy Yeleswaram of 404 shares of Rapport Therapeutics common stock for total proceeds of $20,159.60 during the past three months.

How were the RAPP shares to be sold under Form 144 originally acquired?

The remarks state that the securities to be sold were acquired upon the vesting of founders shares during the period from June 9, 2024 through August 20, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:28 PM Accepted by SEC EDGAR 08/24/2026 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002022156
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Rapport Therapeutics, Inc.
SEC File Number	001-42121
Address of Issuer	99 High Street, Suite 2100 Boston MASSACHUSETTS 02110
Phone	8573218020
Name of Person for Whose Account the Securities are To Be Sold	KRISHNASWAMY YELESWARAM
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11472	553409.28	47978286	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/09/2024	Founders Shares	Issuer			11472	06/09/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KRISHNASWAMY YELESWARAM 99 High Street, Suite 2100 Boston MA 02110	Common	08/19/2026	404	20159.60

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of founders shares during the period of 6/09/2024 through 8/20/2024
Date of Notice	08/24/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Krishnaswamy Yeleswaram
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)